Issue Date: May 23, 2016
Understanding ‘chemo brain’
About 30% of cancer patients who receive chemotherapy later suffer from so-called chemo brain, a condition characterized by memory loss, attention deficits, and decreased problem-solving abilities. Scientists know little about how anticancer drugs lead to this cognitive decline. But a new study reports that treating rats with the drug carboplatin impairs the release of dopamine and serotonin, which are neurotransmitters that play key roles in many cognitive functions affected by chemo brain (ACS Chem. Neurosci. . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society